Emerging Markets

Abbott, Syngene to open first nutrition R&D center in India

Friday, May 4, 2012 08:01 AM

Abbott, one of India's largest health care companies, is collaborating with Syngene, an Indian CRO and subsidiary of Biocon, to establish its first nutrition R&D center in the country.

More... »


OrbiMed launches $222 million fund in Israel life sciences

Tuesday, April 24, 2012 12:18 PM

OrbiMed, a global investment management firm focused on the healthcare sector, has closed its first investment fund dedicated to life sciences venture capital opportunities based in Israel. The Fund, OrbiMed Israel Partners Limited Partnership, includes an anchor investment provided by the government of Israel, which also provided special economic terms through the initial tender process for the Fund.

More... »


Marken continues expansion with Buenos Aires facility

Tuesday, December 20, 2011 01:39 PM

Marken continues their expansion of services in Latin America, by augmenting their new purpose-built Buenos Aires facility.

More... »

Russia's cancer drug market to grow to $163 million

Wednesday, December 14, 2011 12:48 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has found that the Russian market for non-small-cell lung cancer therapies will grow 3% annually from 2010 to 2015 to $163 million in 2015. According to the Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.

More... »

Middle East region poised for clinical trials growth

Monday, October 24, 2011 08:00 AM

With sponsors and CROs still on the hunt for emerging markets rife with treatment-naive patients and good infrastructure, interest in the Middle East is increasing.

More... »

DIA names director of DIA India

Monday, October 17, 2011 12:00 PM

DIA has named Kaushik Desai as director of DIA India. Kaushik brings to DIA both a deep knowledge of the global regulatory framework and the pharmaceutical environment in India as well as a passion for the vision and mission of the association.

More... »

Actavis expands to Latin America

Friday, October 7, 2011 11:49 AM

Actavis Group CEO Claudio Albrecht has reported a major sales expansion into Latin America, among the world's fastest-growing markets for generic drugs.

More... »

Sponsors must consider the challenges as well as advantages when moving trials to emerging markets

Monday, January 10, 2011 07:00 AM

As drug sponsors increasingly look to emerging markets for greater patient access and lower trial costs, they must also consider the potential disadvantages of moving operations to a developing country when choosing the best location for a clinical trial, according to new research from Cutting Edge Information.

More... »

Florida site group goes global with Panama City office

Monday, January 3, 2011 07:00 AM

Sponsors and CROs have gone international. Are sites next?

More... »

Synexus sees clinical trials rise 25% in Hungary

Tuesday, August 24, 2010 07:00 AM

Synexus’ clinical trials activity in Hungary increased by 25% during the first half of 2010. The company’s Dedicated Research Centre has been operating in Hungary since 2006 and has become one of the company’s most successful CEE sites. The Budapest-based operation has been involved in more than 74 trials since being acquired by Synexus, and has randomized over 600 patients. Dr Erika Nemeth, Synexus’ country manager in Hungary, said the trend of more clinical trials being conducted in Hungary is set to continue: “The high standards of medical and research & development expertise in Hungary has resulted in high levels of participation in clinical trials and means that pharma and biotech companies remain keen to include Hungary as part of their global clinical trial programs.” The prevalence of chronic conditions including CVD and COPD among the Hungarian population, together with little preventative healthcare and healthcare education, means the treatment naïve population remains substantial and therefore attractive for clinical trials. Also, the pharmaceutical market in Hungary is set to increase significantly in the coming decade, encouraging the major players to establish a stronger and more proactive presence there before their new drugs come to market. Synexus CEO Michael Fort said the productivity of investigators, the attractive overhead costs and the world-renowned medical expertise and innovation in Hungary make it one of his company’s key areas for future development.

More... »

`

CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs